Aradigm gains $4.75M in private placement as it advances inhaled liposomal ciprofloxacin
This article was originally published in Scrip
Executive Summary
Aradigm has in the works a private placement for $4.75 million, just as it has announced progress with the development of its inhaled liposomal formulation of ciprofloxacin.